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 2 
Abstract 22 
Aspergillus flavus is one of the most common isolates from patients with fungal infections. 23 
Aspergillus infection is usually treated with antifungal agents, but side effects of these agents 24 
are common. Trehalase is an essential enzyme involved in fungal metabolism and the trehalase 25 
inhibitor, validamycin A, has been used to prevent fungal infections in agricultural products. 26 
In this study, we observed that validamycin A significantly increased trehalose levels in A. 27 
flavus conidia and delayed germination, including decreased fungal adherence. In addition, 28 
validamycin A and amphotericin B showed a combinatorial effect on A. flavus ATCC204304 29 
and clinical isolates with high minimum inhibitory concentrations (MICs) of amphotericin B 30 
using checkerboard assays. We observed that validamycin A and amphotericin B had a 31 
synergistic effect on A. flavus strains resistant to amphotericin B.  The MICs in the combination 32 
of validamycin A and amphotericin B were at 0.125 μg/mL and 2 μg/mL, respectively. The 33 
FICI of validamycin A and amphotericin B of these clinical isolates was about 0.25-0.28 with 34 
synergistic effects.  No drug cytotoxicity was observed in human bronchial epithelial cells 35 
treated with validamycin A using LDH-cytotoxicity assays. In conclusion, this study 36 
demonstrated that validamycin A inhibited the growth of A. flavus and delayed conidial 37 
germination. Furthermore, the combined effect of validamycin A with amphotericin B 38 
increased A. flavus killing, without significant cytotoxicity on human bronchial epithelial cells. 39 
We propose that validamycin A could potentially be used in vivo as an alternative treatment 40 
for A. flavus infections. 41 
 42 






Aspergillus flavus is a fungus commonly found in the environment and when it contaminates 48 
food, it produces aflatoxins which are associated with increased risk of developing liver cancer 49 
in humans [1, 2]. Moreover, A. flavus is an infectious fungus and can colonise organs leading 50 
to conditions such as keratitis, cutaneous infections, sinusitis, and invasive pulmonary 51 
aspergillosis [3-5]. Knowledge and understanding of the epidemiology and pathogenesis of A. 52 
flavus infection in humans is still very limited as there are only a few reports on A. flavus in 53 
comparison to other Aspergillus species [6]. For example, it has been reported that A. flavus is 54 
a common cause of cutaneous infections and sinusitis in India [4, 5]. 55 
Initial treatment of Aspergillus invasive infections (invasive aspergillosis) begins with 56 
antifungal agents, particularly azoles. Voriconazole is a drug of choice in patients with 57 
aspergillosis [7, 8] but serious adverse reactions have been reported in many studies, such as 58 
transient visual disturbances, hepatotoxicity, tachyarrhythmias, and QTc interval prolongations 59 
[8]. Amphotericin B is a fungicidal polyene agent, which is an alternative, relatively cheap 60 
treatment for aspergillosis [7, 8] but it also has serious side effects (e.g. nephrotoxicity) [9]. 61 
Owing to socioeconomic status of patients and availability of this agent, the use of 62 
amphotericin B as a treatment against aspergillosis is very common in developing countries, 63 
including Thailand [10-12]. Unfortunately, recent studies have demonstrated increasing 64 
incidence of A. flavus clinical isolates with resistance to amphotericin B [13, 14]. 65 
 Although patients with aspergillosis are treated with standard antifungal therapy as 66 
mentioned, evidence shows that the morbidity and mortality rates in patients with these 67 
infections are still high (up to 80%) [15 ] . Therefore, the discovery of novel antifungal agents 68 
with fewer side effects is crucial for treatment of aspergillosis. Many studies have reported 69 
virulence factors and metabolic pathways that are specific to this fungus, and these could 70 
potentially be new targets for the development of antifungal agents [16, 17]. For example, 71 
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trehalose is a disaccharide that is only found in bacteria, plants, insects, and invertebrates. It is 72 
composed of two glucose molecules conjugated with α, α- 1 , 1 -glycosidic linkage and serves 73 
as an energy source, particularly when fungi are exposed to environmental stresses such as 74 
cold, heat and desiccation [18-20].  75 
There are three different enzymes involved in trehalose pathway; a) trehalose-6-76 
phosphate synthase (Tps1p), b) trehalose-6-phosphate phosphatase (Tps2p) and c) trehalase 77 
(Figure 1). Tps1p converts UDP-glucose and glucose 6-phosphate into trehalose 6-phosphate 78 
[20].  Tps2p enzyme removes phosphate from trehalose 6-phosphate to form trehalose.  These 79 
enzymes in the trehalose pathway are essential for the growth of Candida albicans, 80 
Cryptococcus neoformans, and Aspergillus fumigatus [18, 21-23]. Trehalase hydrolyzes and 81 
degrades trehalose into two glucose molecules [24]. There are two types of trehalase found in 82 
Saccharomyces cerevisiae [25], which are neutral trehalase and acid trehalase (Figure 2). 83 
Neutral trehalase (Nth1p) is found in the cytosol and works at an optimum pH of 7.0 [24, 26] 84 
whereas acid trehalase (Ath1p) is a cell wall-linked enzyme and works at an optimum pH of 85 
5.0 [27-29]. It has been reported that the trehalose pathway is involved in the pathogenesis of 86 
fungal infections in human (e.g. C. albicans, C. neoformans, A. fumigatus) [19, 21-23, 30-32]. 87 
In previous studies, it was demonstrated that Rhizoctonia solani, a rice fungal pathogen, 88 
was inhibited by the trehalase inhibitor, validamycin A [33-35]. Validamycin A  was originally 89 
isolated from Streptomyces hygroscopicus var. limoneus, [33, 36, 37] and it was shown that it 90 
inhibited branching of R. solani [33, 38]. Another study found that validamycin A delayed 91 
conidial production of Fusarium culmorum [38]. However, the effectiveness of validamycin A 92 
against human fungal pathogens and its toxicity on human cells are unknown. Here, we 93 
investigated the effects of validamycin A alone and in combination with amphotericin B on the 94 
growth of A. flavus, including the cytotoxicity of validamycin A to a human cell line. 95 
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 96 
Materials and Methods 97 
Fungal strains, media, and conditions  98 
A. flavus ATCC 204304 was cultured on Sabouraud Dextrose Agar (SDA, Oxoid, 99 
Thermo Fisher Scientific) petri-dish plates at 37°C for three days before harvesting A. flavus 100 
conidia using sterile distilled water with 0.01% tween 80. Briefly, 5 mL of sterile distilled water 101 
with 0.01% tween 80 was utilized to harvest A. flavus conidia on SDA petri-dish plates using 102 
cell scrapers. The mixture between distilled water with tween 80 and A. flavus conidia was 103 
filtered using miracloth. A number of conidia were counted from the filtrate using a 104 
hemocytometer. Then 103 conidia were inoculated into culture media [39], i.e. glucose peptone 105 
agar (peptone 10 g, glucose 20 g, agar 20 g, distilled water 1000 ml, pH 6.8–7.0), trehalose 106 
peptone agar (peptone 10 g, trehalose 10 g, agar 20 g, distilled water 1000 ml, pH 6.8–7.0), and 107 
peptone agar (peptone 10 g, agar 20 g, distilled water 1000 ml, pH 6.8–7.0), incubated at 37°C 108 
for 2-5 days. The radial fungal growth was measured in three biological replicates.  109 
 A. flavus clinical isolates were obtained from the Mycology laboratory, Department of 110 
Microbiology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn 111 
Memorial Hospital during 2019. Patient characteristics were collected from medical 112 
records/charts. Patients with invasive aspergillosis (IA) were classified as proven, probable, 113 
and possible invasive aspergillosis, according to EORTC/MSG criteria [40, 41]. 114 
 115 
Trehalose measurements  116 
Conidia of A. flavus ATCC 204304 from SDA treated with or without 1 µg/mL validamycin A 117 
were collected at day 5 after incubation at 37°C.  Trehalose levels of A. flavus conidia were 118 
measured, as previously described [42]. Briefly, 2×108 conidia in 500 uL distilled water with 119 
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tween 80 were boiled at 100oC for 20 min and centrifuged at 11,000xg for 10 min. The 120 
supernatant was collected for trehalose measurement (with biological triplicates) using the 121 
glucose oxidase assay protocol (Sigma; GAGO20). The reaction was measured at 490 nm using 122 
a spectrophotometer (Lambda 1050+ UV/Vis/NIR, PerkinElmer, USA). 123 
 124 
Germination assay 125 
Conidia of A. flavus ATCC 204304 at 1×108 cells were incubated in 10 mL Sabouraud dextrose 126 
broth at 37°C in an orbital shaker at 200 rpm. The cultured broth (500 µL) was used for 127 
counting percentage of germlings. The germinated conidia are counted using a microscope. At 128 
each time point, 100 conidia were counted and the number of germinated conidia were 129 
calculated as a percentage out of total 100 conidia [43].  Each strain was cultured up to 24 h at 130 
37°C in three biological replicates [44].  131 
 132 
XTT assay   133 
XTT assays (sodium 2,3 -bis (2-methoxy-4-nitro-5-sulfophenyl) -5- [(phenylamino) -carbonyl] 134 
-2H-tetrazolium) were performed as described previously [45, 46]. Briefly, 103 conidia of A. 135 
flavus ATCC 204304 were incubated with different culture media with or without validamycin 136 
A in 96-well plate at 37°C for 18 h. XTT solution (0.5 mg/mL in PBS) was added into each 137 
well, and incubated at 37°C for 15 min. The plate was centrifuged and the supernatant was 138 
collected to measure the OD at 490 nm using a spectrophotometer (Lambda 1050+ 139 
UV/Vis/NIR, PerkinElmer, USA).  140 
 141 
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Crystal violet adherence assay 142 
105 conidia per mL of A. flavus ATCC204304 were incubated in 100 µL of Sabouraud dextrose 143 
broth in each well of plastic U-bottomed 96-well plates at 37oC for 24 h. After washing each 144 
well twice with sterile distilled water gently, 0.1% crystal violet were utilized to stain for 10 145 
min. Sterile distilled water was then utilized to wash twice and 100% ethanol was used to 146 
destain for 10 min. Supernatants were then measured at 600 nm using a spectrophotometer 147 
(Lambda 1050+ UV/Vis/NIR, PerkinElmer, USA) [47]. 148 
 149 
Broth microdilution assay and checkerboard assay 150 
The CLSI broth microdilution M38 method was performed to observe the minimum inhibitory 151 
concentrations (MICs) of amphotericin B for A. flavus ATCC 204304 and clinical isolates  [48]. 152 
The additive/synergistic effect of validamycin A and amphotericin B were identified using the 153 
checkerboard assays [49]. Fractional inhibitory concentration index (FICI) was calculated for 154 
each antifungal drug, in each combination used, with the following formula [49]:   155 
FIC A (MICA/MICA+B) + FIC B (MICB/MICA+B) = FICI 156 
 FICI results were determined as synergy: <0.5; additivity: 0.5-1; indifference: >1-4; 157 
and antagonism: >4. 158 
 159 
Cell line and culture 160 
BEAS-2B (Human bronchial epithelial cell line) (ATCCÒ CRL9609TM) was cultured with 161 
Bronchial Epithelial Cell Growth Basal Medium (BEBM) in tissue culture flasks coated with 162 
0.01 mg/mL fibronectin, 0.03 mg/mL bovine collagen type I, and 0.01 mg/mL bovine serum 163 
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albumin (BSA). The cells were incubated at 37ºC in a humidified environment with 5% CO2 164 
[50]. 165 
 166 
Cytotoxicity assay 167 
The cytotoxicity of validamycin A towards human epithelial cell lines was performed using a 168 
Lactate Dehydrogenase (LDH)-Cytotoxicity Colorimetric Assay Kit II (Biovision Inc, CA, 169 
USA).  Briefly, 1 x 104 BEAS-2B cells were incubated with 50 µL of DMEM in a pre-coated 170 
96-well plate and then validamycin A was added at different concentrations (1µg/mL - 171 
1mg/mL, final concentration). LDH reaction mixture was added and the cells were incubated 172 
at 37°C for 30 min. LDH released from the cells was measured at 450 nm using a 173 
spectrophotometer. The percentage of cytotoxicity was calculated using the following formula: 174 
Cytotoxicity (%)=  (test sample - low control) x 100
( high control - low control) 
 175 
High control is cells with lysis buffer while low control is cells alone as a background. 176 
 177 
Statistical analysis 178 
All statistical analyses were conducted with Prism 8 software (GraphPad Software, Inc., San 179 
Diego, CA). Comparison between groups performed with unpaired two-tailed Student’s t-tests 180 
for two data groups and one-way ANOVA tests with post-hoc Bonferroni’s multiple 181 
comparisons tests for more than two data groups. Error bars represent standard errors of the 182 
means. Significant differences were considered when p-value < 0.05. 183 
 184 
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Ethics statement 185 
This study was approved by the Institutional Review Board (IRB No. 546/60), Faculty of 186 
Medicine, Chulalongkorn University, Bangkok, Thailand. 187 
 188 
Results 189 
Trehalase homologs in Aspergillus flavus 190 
To identify trehalase enzyme homologs in A. flavus, a BLASTp search was performed on S. 191 
cerevisiae and A. fumigatus and compared with A. flavus. The protein data from FungiDB 192 
database and Simple Modular Architecture Research Tool (SMART) were used to compare 193 
putative protein domains among trehalase enzymes from S. cerevisiae (Sc), A. fumigatus (Afu) 194 
and  A. flavus (Afla) (Database: https://fungidb.org, http://smart.emblheidelberg.de/). 195 
  The results showed that AFLA_090490 protein, containing one signal peptide at 196 
positions 1-18 and two O-glycosyl hydrolase domains (EC 3.2.1) at positions 70-339 and 407-197 
638, was similar to acid trehalase of S. cerevisiae and A. fumigatus (Figure 1A). AFLA_052430 198 
protein, containing a neutral trehalase calcium-binding domain at position 105-134 and an O-199 
glycosyl hydrolase domain (EC 3.2.1) at position 162-725, was similar to neutral trehalase of 200 
S. cerevisiae and A. fumigatus (Figure 1B). Our findings suggest that A. flavus has both acid 201 
and neutral trehalases, as seen in S. cerevisiae and A. fumigatus. 202 
 Next, we investigated the ability of A. flavus to utilize trehalose as a sole carbon source. 203 
The result showed that growth and viability of A. flavus on glucose peptone media and trehalose 204 
peptone media was similar (Figure 2A and 2B). This finding supports the idea that A. flavus 205 
utilizes trehalose as a sole carbon source and implies that it degrades extracellular trehalose 206 
into glucose for its growth. 207 
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Growth inhibition and decreased fungal adherence of Aspergillus flavus by validamycin 208 
A 209 
To observe the inhibitory effect of validamycin A on A. flavus ATCC204304, broth 210 
microdilution and XTT assays were performed. The results showed that the minimal inhibition 211 
concentration (MIC) of validamycin A against A. flavus was 1 µg/mL (Table 1), and the 212 
viability of A. flavus ATCC204304 after validamycin A treatment at this concentration was 213 
significantly decreased when compared to 0.5 µg/mL of validamycin A, 0.25 µg/mL of 214 
amphotericin B and the control group (Figure 3).   215 
 Next, A. flavus ATCC204304 was cultured and treated with or without 0.5 and 1 216 
µg/mL of validamycin A and trehalose levels in the conidia were measured. The results 217 
demonstrated that conidia collected from A. flavus treated with validamycin A showed 218 
significantly higher levels of trehalose than the control (untreated) group, suggesting that 219 
validamycin A inhibited trehalase enzymes in the conidia of A. flavus (Figure 4A). In addition, 220 
the rate of conidial germination was investigated in A. flavus conidia treated with 1 µg/mL of 221 
validamycin A. The results showed that validamycin A significantly delayed conidial 222 
germination of A. flavus ATCC204304 particularly at 10 and 12 h (Figure 4B). These data 223 
suggest that validamycin A delays conidial germination of A. flavus via inhibition of trehalase 224 
enzymes.  225 
 To observe the effect of validamycin A to exopolysaccharides of A. flavus, the crystal 226 
violet adherence assays were performed. We observed that 1 µg/mL of validamycin A 227 
decreased the adherence property of A. flavus ATCC204304 (Figure 4C). These data suggest 228 
that validamycin A affects the fungal adherence of A. flavus. 229 
Synergistic effects of validamycin A and amphotericin B on Aspergillus flavus clinical 230 
isolates 231 
 11 
Antifungal susceptibility tests of A. flavus ATCC204304 were performed according to the 232 
CLSI broth microdilution method (CLSI M38, 2017). The results demonstrated that the MIC 233 
of validamycin A and amphotericin B alone against A. flavus ATCC204304 was 1 and 4 µg/mL, 234 
respectively (Table 1).  Furthermore, the fractional inhibitory concentration index (FICI) was 235 
0.625 with the concentrations of validamycin A and amphotericin B at 0.125 µg/mL and 2 236 
µg/mL, respectively (Table 1). This finding suggests that validamycin A and amphotericin B 237 
have an additive effect on A. flavus ATCC204304.   238 
 To confirm the combinative effects of validamycin A and amphotericin B, A. flavus 239 
clinical isolates (n=3) with high MICs of amphotericin B (> 4 µg/mL) (Table 1) were chosen 240 
to perform checkerboard assays. Interestingly, the FICI was 0.25-0.28, suggesting a synergistic 241 
effect between these two drugs on these clinical isolates (Table 1).   242 
No cytotoxicity of validamycin A to human bronchial epithelial cells 243 
Human bronchial epithelial cells, BEAS-2B, were treated with or without validamycin A 244 
including amphotericin B at different concentrations. The results demonstrated that 0.125, 0.5, 245 
1 µg/mL of validamycin A,  1, 2 µg/mL of amphotericin B, and a combination of these two 246 
drugs concentrations of 0.125 µg/mL of validamycin A, and 2 µg/mL of amphotericin B 247 
showed no significant cytotoxicity to human bronchial epithelial cells (Figure 5). 248 
 249 
Discussion 250 
The trehalose pathway is a major mechanism for growth and metabolism of many fungi; 251 
however, the presence of trehalase enzymes in many of these fungi is still unknown [19, 21-23, 252 
30-32]. Validamycin A is a trehalase enzyme inhibitor produced by Streptomyces 253 
hygroscopicus and is used for fungal inhibition in plants and insects [33, 36, 37, 51, 52]. From 254 
many previous reports, in plants and insects, the effect of validamycin A is to inhibit trehalase 255 
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activity in their cells [53-56]. In a rice fungal pathogen, Rhizoctonia solani, validamycin A was 256 
shown to inhibit trehalase activity, but not cellulase, pectinase, chitinase, amylase, or 257 
glucosidases [57]. Additionally, validamycin A also inhibited the growth of Rhizoctonia solani, 258 
and Fusarium culmorum [33, 38]. However, there are only few studies demonstrating the 259 
effects of validamycin A on human fungal pathogens [58]. From our study, we observed that a 260 
human fungal pathogen, A. flavus, had two trehalase enzymes that shared similar conserved 261 
domains and possessed high similarity and identity to Saccharomyces cerevisiae and 262 
Aspergillus fumigatus (Figure 1A&B), including Rhizoctonia solani and Candida albicans 263 
(Figure S1A&B). Therefore, we hypothesize that validamycin A may inhibit trehalase enzyme 264 
activity in A. flavus similar to previous reports [33, 38, 57]. 265 
 In this study, we investigated the presence of trehalase enzymes, and the effect of the 266 
trehalase inhibitor, validamycin A, on the growth of a common pathogenic fungus in humans, 267 
A. flavus. The results showed that  A. flavus possesses trehalase homologs and grew on trehalose 268 
peptone media, similar to growth on glucose peptone media (Figure 2A, B). These findings 269 
imply that A. flavus utilize trehalase enzymes to degrade trehalose for use as a carbon source 270 
and energy. In addition, we observed inhibitory effects of validamycin A on the growth of A. 271 
flavus (Figure 3). This finding suggests that trehalase activity is required for A. flavus growth. 272 
However, direct evidence, such as genetic approaches (e.g. generating trehalase gene-deletion 273 
mutants) to support the importance of trehalase is needed to confirm this observation.   274 
In a previous study, it was found that validamycin A increased trehalose levels in a 275 
pathogenic fungus, C. albicans [ 5 8 ] . This result is similar to our findings that showed an 276 
increase in trehalose levels of A. flavus conidia after validamycin A treatment (Figure 4A). 277 
However, further trehalase activity assay using high-performance liquid chromatography 278 
(HPLC) is also necessary to confirm the effect of validamycin A against trehalase enzymes in 279 
A. flavus. As the trehalose pathway is crucial in the early stages of conidial germination [18, 280 
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19, 47, 59], we further investigated the effect of validamycin A on conidial germination of A. 281 
flavus. Expectedly, validamycin A significantly delayed conidial germination of A. flavus 282 
(Figure 4B). Therefore, these observations suggest that the inhibition of trehalase enzymes 283 
depletes the source of energy and the growth for A. flavus. Nonetheless, we observed that 284 
conidial germination in the presence of validamycin A was not different from the untreated 285 
group at 24-hour incubation. This result suggests that A. flavus could probably increase conidial 286 
germination by alternative pathways following trehalase inhibition (e.g. mannitol pathway) 287 
[60, 61]. A wide variety of different media is still necessary to be further investigated for the 288 
trehalose phenotypes in A. flavus. 289 
In addition, this study further investigated the combinative effect between 290 
validamycin A and amphotericin B on A. flavus ATCC204304, which is a standard strain for 291 
the antifungal susceptibility test. The result demonstrated that these two drugs showed an 292 
additive effect on growth inhibition of A. flavus. Interestingly, the combination of these drugs 293 
had a synergistic effect on A. flavus clinical isolates with high MICs of amphotericin B. 294 
Although the cutoff value of MIC for amphotericin B resistance in A. flavus was unknown, 295 
Barchiesi et al. suggested that MIC of amphotericin B ³ 2 µg/mL should be considered as a 296 
resistant strain [48, 62].  297 
Trehalose pathway is clearly associated with cell wall components, including chitin 298 
and beta-glucan, as shown in many previous reports [18, 19, 42, 47]. Disturbance in 299 
substrates of trehalose or enzymes or proteins associated with the trehalose pathway in 300 
Aspergillus fumigatus would lead to changes on the cell wall components and structure [18, 301 
19, 42, 47]. Furthermore, trehalose level and proteins associated with the trehalose pathway 302 
may affect exopolysaccharide galactosaminogalactans (GAGs), which are important for 303 
fungal adherence and biofilm formation, as shown in A. fumigatus previous reports [42, 47]. 304 
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In this study, we also observed that validamycin A decreased fungal adherence (Figure 4C). 305 
These data imply that the structure or components of exopolysaccharide GAGs may be 306 
affected by validamycin A. 307 
Besides, trehalase enzymes in many eukaryotic organisms may play important roles in 308 
the carbon metabolism, chitin biosynthesis, and stress tolerance, i.e. sucrose and trehalose 309 
homeostasis in Arabidopsis thaliana and Phaseolus vulgaris, regulation of chitin biosynthesis 310 
in insects, and carbon partitioning in many plants [63-70]. Therefore, we hypothesize that 311 
inhibition of trehalase enzyme via validamycin A may change the structure and components 312 
of fungal cell wall and exopolysaccharide through changes in the carbon metabolism of A. 313 
flavus leading to increased permeability and synergistic effects of amphotericin B against A. 314 
flavus in the presence of validamycin A. However, further studies of cell wall/GAGs 315 
structures via electron microscope and cell wall/GAGs components through HPLC, including 316 
RNA sequencing and metabolomic analyses, are necessary to decipher the effect of 317 
validamycin A in A. flavus [18, 47].  318 
Additionally, MICs of validamycin A in each A. flavus clinical isolate were varied. 319 
This variation of MICS of validamycin A in these clinical isolates is probably due to the 320 
difference in the cell wall/GAGs structure and components of each strain (e.g. glucan or 321 
chitin), as a previous study showed that amphotericin B-resistant A. flavus contained higher 322 
(1,3)-b-D-glucan in their cells wall than the sensitive strains [71]. Furthermore, previous 323 
studies suggest that some clinical isolates of A. fumigatus had different phenotypes including 324 
cell wall components and virulence [72, 73].  325 
We further characterized these clinical isolates and observed that the growth rate and 326 
conidial trehalose levels showed no difference from A. flavus ATCC204304 (Figure 327 
S2A&B). However, these isolates possessed different fungal adherence property (Figure 328 
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S2C). Different exopolysaccharide components and/or structure of these isolates may lead to 329 
decreased permeability of amphotericin B and validamycin A into fungal cell membrane and 330 
cytoplasm affecting MICs in each clinical isolate. Nonetheless, the cell wall/GAGs structure 331 
and components of these clinical isolates need to be further studied. Moreover, more clinical 332 
isolates and animal models are also necessary to confirm synergistic effects between 333 
validamycin A and amphotericin B.  334 
 Cytotoxicity of validamycin A was tested in our study, and the result demonstrated 335 
that validamycin A at concentrations showing synergistic effects on A. flavus had no 336 
cytotoxicity on human bronchial epithelial cells (Figure 5). Nevertheless, different human cell 337 
lines together with different concentrations of validamycin A and amphotericin B are still 338 
needed to be further investigated for the cytotoxicity. In addition, in vivo studies are required 339 
as acute toxicity was found in rodents at very high doses of validamycin A 340 
(https://pubchem.ncbi.nlm.nih.gov/compound/Validamycin-A). For future in vivo survival 341 
studies, different concentrations of validamycin A, i.e. 0.125 and 1 µg/mL with or without the 342 
combination of amphotericin B, and different routes of administration, e.g. oral gavage, 343 
intraperitoneal route, or intravenous route, are necessary to be further investigated. 344 
 In conclusion, this study demonstrated that validamycin A delayed conidial 345 
germination and inhibited the growth of A. flavus. Moreover, a combination between 346 
validamycin A and amphotericin B, showed a synergistic effect on amphotericin B-resistant A. 347 
flavus clinical isolates. The cytotoxicity of validamycin A to human bronchial epithelial cells 348 
was not observed in our study. Therefore, we propose that validamycin A could potentially be 349 
used as adjunctive therapy in patients with A. flavus infection, particularly those who are 350 
infected with amphotericin B-resistant strains. 351 
 352 
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Supplementary materials  374 
Figure S1. Aspergillus flavus shares similar trehalase enzymes with Rhizoctonia solani and 375 
Candida albicans. A) Percentages of identity and similarity of AFLA_090490 (B8NLC2) : R. solani 376 
AGM46811.1 (R4VJL2) and  AFLA_090490 (B8NLC2) : C. albicans SC5314 acid trehalase (Q5AAU5) 377 
from BLASTp analyses, are 31% identity, 47% similarity, and 32% identity, 48% similarity, respectively. 378 
AFLA: Aspergillus flavus; Glycosyl hydrolase family 65 (Glyco_hydro_65N; Glyco_hydro_65m); 379 
Trehalase:  Trehalose hydrolysis domain. (Adapted from SMART analyses (http://smart.embl-380 
heidelberg.de/)). B) Percentages of identity and similarity of AFLA_052438 (B8NS12) : R. solani 381 
AGM46812.1 (R4VM92) and  AFLA_052438 (B8NS12) : C. albicans P78042 neutral trehalase from 382 
BLASTp analyses, are 55% identity, 70% similarity, and 55% identity, 71% similarity, respectively.  AFLA: 383 
Aspergillus flavus; Trehalase_Ca-bi: Neutral trehalase calcium-binding domain;  Trehalase:  Trehalose 384 
hydrolysis domain. (Adapted from SMART analyses (http://smart.embl-heidelberg.de/)). 385 
 386 
Figure S2. Different Aspergillus flavus isolates show no difference in the radial growth 387 
rate and conidial trehalose levels, but possess different fungal adherence property. A) 388 
Aspergillus flavus ATCC 204304 and three clinical isolates were incubated at 37⁰C on glucose media. The 389 
radial growth of these fungal growths was measured on the third day of incubation. Data are presented as 390 
means ± SE from three biological replicates. No significant difference was observed (one-way ANOVA with 391 
post-hoc Bonferroni's test). B) Aspergillus flavus ATCC 204304 and three clinical isolates were cultured at 392 
37⁰C on Sabouraud dextrose agar for five days with or without 1 µg/mL validamycin A. Trehalose assays 393 
were performed to measure trehalose levels in the conidia using glucose oxidase assays. Data are presented 394 
as means ± SE from three biological replicates. No significant difference was observed (one-way ANOVA 395 
with post-hoc Bonferroni's test). C) Aspergillus flavus ATCC 204304 and three clinical isolates were 396 
cultured at 37⁰C in Sabouraud dextrose broth with or without 1 µg/mL validamycin A in 96-well plates for 397 
24 hours and the crystal violet adherence assays were performed. Data are presented as means ± SE from 398 
three biological replicates. *, P-value < 0.05; **, P-value < 0.01 (one-way ANOVA with post-hoc 399 
Bonferroni's test compared to ATCC204304 strain). 400 
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Figure 1. Aspergillus flavus possesses trehalase homologs. A) Percentages of identity and 590 
similarity of ScAth1p (YPR026W) : AFLA_090490 (B8NLC2) and  Afu3g02280 (Q4WFG4) 591 
: AFLA_090490 (B8NLC2) from BLASTp analyses, are 29% identity, 46% similarity, and 592 
68% identity, 81% similarity, respectively. ScAth1p:  Saccharomyces cerevisiae acid 593 
trehalase protein; Afu: Aspergillus fumigatus; AFLA: Aspergillus flavus; Glycosyl hydrolase 594 
family 65 (Glyco_hydro_65N; Glyco_hydro_65m). (Adapted from SMART analyses 595 
(http://smart.embl-heidelberg.de/)). 596 
B) Percentages of identity and similarity of ScNth1p (YDR001C) : AFLA_052438 (B8NS12) 597 
and Afu4g13530 (Q4WQP4) : AFLA_052438 (B8NS12) from BLASTp analyses, are 55% 598 
identity, 69% similarity, and 81% identity, 88% similarity, respectively.  ScNth1p:  599 
Saccharomyces cerevisiae neutral trehalase protein; Afu: Aspergillus fumigatus; AFLA: 600 
 26 
Aspergillus flavus; Trehalase_Ca-bi: Neutral trehalase calcium-binding domain;  Trehalase:  601 






Figure 2. Aspergillus flavus utilizes trehalose as a sole carbon source similar to glucose.  608 
A) Aspergillus flavus ATCC 204304 was incubated at 37⁰C on glucose peptone, trehalose 609 
peptone, and peptone alone media. The radial growth of these fungal growths was measured 610 
on the second day of incubation. Data are presented as means ± SE from three biological 611 
 27 
replicates. *, P-value < 0.05; **, P-value < 0.01 (one-way ANOVA with post-hoc Bonferroni's 612 
test). B) Aspergillus flavus ATCC 204304 was incubated at 37⁰C on glucose peptone, trehalose 613 
peptone, and peptone alone liquid media for 24 hours and viability tests using XTT assays were 614 
performed. Data are presented as means ± SE from three biological replicates. *, P-value < 615 
0.05 (one-way ANOVA with post-hoc Bonferroni's test). 616 
 617 
Figure 3. Validamycin A inhibits the growth of Aspergillus flavus  618 
Aspergillus flavus ATCC204304 was cultured at 37°C in RPMI media in 24-well plate for 18 619 
hours. Fungal viability was measured by XTT assays at 490 nm. Amp: Amphotericin B at 0.25 620 
µg/mL. Data are presented as means ± SE from three biological replicates. *, P-value < 0.05; 621 
**, P-value < 0.01; ***, P-value < 0.001 (one-way ANOVA with post-hoc Bonferroni's test 622 
compared to fungus alone) 623 
 28 
 624 
Figure 4. Validamycin A increases trehalose levels in Aspergillus flavus conidia with 625 
delayed conidial germination and decreased fungal adherence. 626 
A) Aspergillus flavus ATCC 204304 was cultured at 37⁰C on Sabouraud dextrose agar for five 627 
days with or without 1 µg/mL validamycin A. Trehalose assays were performed to measure 628 
trehalose levels in the conidia using glucose oxidase assays. Data are presented as means ± SE 629 
from three biological replicates. ***, P-value < 0.001 (unpaired two-tailed Student’s t-test 630 
compared to the control). B) Aspergillus flavus ATCC 204304 was cultured at 37⁰C in 631 
Sabouraud dextrose broth with or without 1 µg/mL validamycin A in an orbital shaker at 200 632 
B 
 29 
rpm. Conidial germination at each time point was counted and calculated. Data are presented 633 
as means ± SE from three biological replicates. **, P-value < 0.01 (unpaired two-tailed 634 
Student’s t-test compared to the control). C) Aspergillus flavus ATCC 204304 was cultured at 635 
37⁰C in Sabouraud dextrose broth with or without 1 µg/mL validamycin A in 96-well plates 636 
for 24 hours and the crystal violet adherence assays were performed. Data are presented as 637 
means ± SE from three biological replicates. **, P-value < 0.01 (unpaired two-tailed Student’s 638 





Figure 5. Validamycin A and the combination of validamycin A and amphotericin B have 644 
no cytotoxic effect on human bronchial epithelial cells. The cytotoxicity test was performed 645 
to observe the toxicity of validamycin A and amphotericin B on BEAS-2B cells using lactate 646 
dehydrogenase (LDH)-Cytotoxicity Colorimetric Assay Kit II. Cell cultures were incubated at 647 
 30 
37ºC in a humidified environment containing 95% air-5% CO2. After 24 hours, LDH reaction 648 
mixture was added (25 µl), incubated at 37°C for 30 minutes. Then ODs were measured at 450 649 
nm using a spectrophotometer. Data are presented as means ± SE from three biological 650 

















Table 1 Minimum inhibitory concentrations (MICs) of validamycin A alone, amphotericin B alone, or validamycin A in combination with 667 
amphotericin B on Aspergillus flavus ATCC204304 and Aspergillus flavus from clinical isolates. Table also contains patient characteristics, i.e. 668 
specimen source, diagnosis, and underlying disease, including the fractional inhibitory concentration index (FICI) and the interpretation of FICI 669 









MICs of single agent (µg/mL) MICs of combined agents (µg/mL) 
FICI  (µg/mL) Interpretation 





  1 4 0.125 2 0.625 A 













>128 8 0.125 2 <0.251 S 









virus cirrhosis 1 8 0.0312 2 0.281 S 













>128 8 0.0039 2 <0.250 S 
